Efficacy and safety of Tildrakizumab in Australian patients with chronic plaque psoriasis in a phase 3 clinical trial

被引：0
|
作者：
Foley, P. [1 ,2 ]
Spelman, L. [3 ,4 ]
Fernandez-Penas, P. [5 ,6 ]
Freeman, M. [7 ]
Sinclair, R. [8 ]
Horton, J. [9 ]
Rozzo, S. J. [10 ]
Kurstjens, N. [11 ]
Shumack, S. [12 ]
机构：
[1] Skin & Canc Fdn Inc, Carlton, Vic, Australia
[2] Prob Med Res, Carlton, Vic, Australia
[3] Verac Clin Res, Brisbane, Qld, Australia
[4] Prob Med Res, Brisbane, Qld, Australia
[5] Westmead Hosp, Dept Dermatol, Westmead, NSW, Australia
[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[7] Skin Ctr, Benowa, Qld, Australia
[8] Univ Melbourne, Melbourne, Vic, Australia
[9] Forest Hill Dermatol & Skin Canc Clin, Forest Hill, Vic, Australia
[10] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[11] Sun Pharma ANZ, Macquarie Pk, NSW, Australia
[12] Univ Sydney, Sydney, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
    Blauvelt, Andrew
    Sofen, Howard
    Papp, Kim
    Gooderham, Melinda
    Zhao, Yang
    Lowry, Simon
    Parno, Jeff
    Li, Qing
    la Rosa, Carmen
    Reich, Kristian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB296 - AB296
  • [2] TILDRAKIZUMAB EFFICACY OVER TIME BY WEEK 28 RESPONSE LEVELS IN TWO PHASE 3 CLINICAL TRIALS IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS
    Blauvelt, Andrew
    Sofen, Howard
    Papp, Kim
    Gooderham, Melinda
    Zhao, Yang
    Lowry, Simon
    Parno, Jeff
    Li, Qing
    La Rosa, Carmen
    Reich, Kristian
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 49 - 49
  • [3] Efficacy of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions to 2 phase 3 clinical studies
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Green, S.
    Li, Q.
    La Rosa, C.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 108
  • [4] TILDRAKIZUMAB EFFICACY OVER TIME BY WEEK 28 RESPONSE LEVELS IN TWO PHASE 3 CLINICAL TRIALS IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS
    Blauvelt, A.
    Sofen, H.
    Papp, K.
    Gooderham, M.
    Zhao, Y.
    Lowry, S.
    Mendelsohn, A.
    Parno, J.
    Li, Q.
    Rosa, C. L.
    Reich, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1602 - 1603
  • [5] Relationships between tildrakizumab dose, exposure, efficacy and safety in phase 3 studies in moderate to severe plaque psoriasis
    Strober, Bruce E.
    Sofen, Howard
    Yamauchi, Paul S.
    Mendelsohn, Alan M.
    Parno, Jeff
    Lowry, Simon
    Rozzo, Stephen J.
    Elewski, Boni E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB117 - AB117
  • [6] Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial
    Duffin, Kristina Callis
    Gold, Linda Stein
    Leonardi, Craig
    Pariser, David
    Green, Lawrence
    Sofen, Howard
    Strober, Bruce
    Chen, Mindy
    Wang, Yao
    Papp, Kim
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB83 - AB83
  • [7] Safety and tolerability of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions of 2 phase 3 studies
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Papp, K. A.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Li, Q.
    Green, S.
    La Rosa, C.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 110 - 111
  • [8] RELATIONSHIPS BETWEEN TILDRAKIZUMAB DOSE, EXPOSURE, EFFICACY AND SAFETY IN PSORIASIS PHASE 3 STUDIES
    Strober, Bruce
    Sofen, Howard
    Yamauchi, Paul
    Mendelsohn, Alan
    Parno, Jeff
    Lowry, Simon
    Rozzo, Stephen
    Elewski, Boni
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 24 - 25
  • [9] A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice
    Burlando, Martina
    Salvi, Ilaria
    Parodi, Aurora
    Cozzani, Emanuele
    [J]. DERMATOLOGY AND THERAPY, 2024, 14 (09) : 2645 - 2652
  • [10] Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)
    Igarashi, Atsuyuki
    Nakagawa, Hidemi
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Imafuku, Shinichi
    Tada, Yayoi
    Honma, Masaru
    Mendelsohn, Alan M.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    [J]. JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 853 - 863
12345